Daiichi Looks To Carve U.S. Anticoagulant Niche With Savaysa
This article was originally published in PharmAsia News
As a late entrant to the novel oral anticoagulant market, the Japanese pharma faces stiff competition from other players, but could still carve out a part of the warfarin market.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.